Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities

Next Previous
Trial Profile

A Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human nerve allograft AxoGen (Primary)
  • Indications Peripheral nerve injuries
  • Focus Registrational; Therapeutic Use
  • Acronyms RECON
  • Sponsors AxoGen Inc

Most Recent Events

  • 25 Aug 2025 According to an AxoGen Inc media release, company announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance Nerve Graft by three months to December 5, 2025.
  • 25 Feb 2025 The U.S. FDA accepted the filing of the Company Biologics License Application (BLA) for Avance Nerve Graft on November 1, 2024, and assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 5, 2025. The Company continues to work through the process with the FDA and anticipates approval in September 2025.
  • 06 Sep 2024 According to an AxoGen Inc media release, Company has requested priority review status for this BLA which, if granted, could reduce the review timeline from the standard 10-month to a priority 6-month review timeline from the date the submission is accepted by FDA. Based on this process, we believe we are on track for FDA determination of approvability between April and September of next year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top